Welcome to Journal Watch. The content you requested requires sign in with a username and password.
Trastuzumab for HER2-Positive Breast Cancer
In these randomized studies of women with nonmetastatic disease, those who received adjuvant chemotherapy plus trastuzumab had a better chance of 2-year disease-free survival than did those who received adjuvant chemotherapy alone.
Sign In
Don't yet have a username or password?
Register now for
Journal Watch e-mail alerts and unlimited online
access to articles 6 months after publication.
Subscribe now for
Full, immediate online access to all Journal Watch content and services.
Already a subscriber? Activate your subscription to receive full online access.
Get full site access with a 7-day site pass for $19